Payment overview · 2025
General Payments
$780.98
35 reported records · 18 companies
Healthcare provider profile · identity verified
Richard Lee Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARROLLTON, MO · NPI 1861448664
Verified facts
What the public records show
CMS Open Payments records show Richard Lee Smith, M.D. received $780.98 in general payments during 2025 across 35 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Invega Sustenna, Jardiance, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 615 claims for Eliquis by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 615 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $106.33 | 13.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $105.26 | 13.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.26 | 12.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $89.14 | 11.4% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.22 | 6.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $50.68 | 6.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.96 | 5.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.02 | 4.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.33 | 3.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.03 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.17 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.49 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.31 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.88 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.64 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.49 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.18 | 1.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.59 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.98 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $123.97 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $105.26 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.14 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $51.22 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $50.68 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.96 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 295 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 154 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
177 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
615 | 74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
97 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
278 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
154 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
116 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
154 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
615 | 74 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2013 | 292 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1645 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 1484 | 235 |
| Potassium Chloride | Potassium Chloride | 1255 | 191 |
| Furosemide | Furosemide | 1149 | 172 |
| Lisinopril | Lisinopril | 1039 | 176 |
| Omeprazole | Omeprazole | 963 | 167 |
| Gabapentin | Gabapentin | 913 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 843 | 127 |
| Metformin Hcl | Metformin Hcl | 806 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 726 | 122 |
| Losartan Potassium | Losartan Potassium | 712 | 124 |
| Meloxicam | Meloxicam | 708 | 119 |
| Sertraline Hcl | Sertraline Hcl | 706 | 100 |
| Eliquis | Apixaban | 615 | 74 |
| Donepezil Hcl | Donepezil Hcl | 614 | 86 |
| Carvedilol | Carvedilol | 598 | 96 |
| Trazodone Hcl | Trazodone Hcl | 579 | 88 |
| Tramadol Hcl | Tramadol Hcl | 576 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 569 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 537 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 514 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 424 | 68 |
| Montelukast Sodium | Montelukast Sodium | 422 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 386 | 68 |
| Famotidine | Famotidine | 371 | 70 |
| Simvastatin | Simvastatin | 368 | 69 |
| Baclofen | Baclofen | 366 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 354 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 62 |
| Allopurinol | Allopurinol | 329 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 325 | 73 |
| Quetiapine Fumarate | Quetiapine Fumarate | 306 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 297 | 47 |
| Jardiance | Empagliflozin | 295 | 36 |
| Divalproex Sodium | Divalproex Sodium | 291 | 42 |
| Spironolactone | Spironolactone | 280 | 48 |
| Xarelto | Rivaroxaban | 278 | 31 |
| Warfarin Sodium | Warfarin Sodium | 271 | 15 |
| Buspirone Hcl | Buspirone Hcl | 269 | 44 |
| Mirtazapine | Mirtazapine | 261 | 52 |
| Ezetimibe | Ezetimibe | 257 | 44 |
| Alendronate Sodium | Alendronate Sodium | 256 | 34 |
| Lorazepam | Lorazepam | 255 | 54 |
| Pregabalin | Pregabalin | 253 | 51 |
| Januvia | Sitagliptin Phosphate | 250 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 248 | 35 |
| Finasteride | Finasteride | 244 | 42 |
| Memantine Hcl | Memantine Hcl | 224 | 38 |
| Bupropion Xl | Bupropion Hcl | 217 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 217 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 37 |
| Alprazolam | Alprazolam | 209 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 206 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 193 | 29 |
| Myrbetriq | Mirabegron | 177 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 172 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 168 | 104 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 162 | 38 |
| Nystatin | Nystatin | 159 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 156 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 154 | 57 |
| Rexulti | Brexpiprazole | 154 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 152 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 150 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 149 | 71 |
| Risperidone | Risperidone | 143 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 141 | 22 |
| Olanzapine | Olanzapine | 140 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 139 | 22 |
| Ozempic | Semaglutide | 139 | 20 |
| Clonazepam | Clonazepam | 138 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 130 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 130 | 18 |
| Prednisone | Prednisone | 130 | 57 |
| Levetiracetam | Levetiracetam | 127 | 20 |
| Temazepam | Temazepam | 123 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 28 |
| Atenolol | Atenolol | 117 | 24 |
| Entresto | Sacubitril/Valsartan | 116 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 113 | 21 |
| Levemir Flexpen | Insulin Detemir | 112 | 27 |
| Celecoxib | Celecoxib | 111 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 111 | 23 |
| Aripiprazole | Aripiprazole | 106 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 102 | 15 |
| Prazosin Hcl | Prazosin Hcl | 102 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 101 | 15 |
| Irbesartan | Irbesartan | 101 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 71 |
| Amiodarone Hcl | Amiodarone Hcl | 99 | 19 |
| Invega Sustenna | Paliperidone Palmitate | 97 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 15 |
| Propranolol Hcl | Propranolol Hcl | 96 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 14 |
| Topiramate | Topiramate | 92 | 17 |
| Glimepiride | Glimepiride | 91 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 91 | 63 |
| Breo Ellipta | Fluticasone/Vilanterol | 90 | 18 |
| Primidone | Primidone | 90 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Latanoprost | Latanoprost | 88 | 15 |
| Lactulose | Lactulose | 87 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 57 |
| Bumetanide | Bumetanide | 84 | 11 |
| Lovastatin | Lovastatin | 81 | 14 |
| Memantine Hcl Er | Memantine Hcl | 81 | suppressed |
| Torsemide | Torsemide | 79 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 56 |
| Glipizide | Glipizide | 77 | 12 |
| Fentanyl | Fentanyl | 76 | 11 |
| Lamotrigine | Lamotrigine | 76 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 75 | 15 |
| Diazepam | Diazepam | 75 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 45 |
| Amoxicillin | Amoxicillin | 73 | 60 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 73 | 18 |
| Ondansetron Odt | Ondansetron | 72 | 22 |
| Digoxin | Digoxin | 71 | suppressed |
| Cefdinir | Cefdinir | 70 | 48 |
| Farxiga | Dapagliflozin Propanediol | 70 | suppressed |
| Levofloxacin | Levofloxacin | 69 | 50 |
| Clonidine Hcl | Clonidine Hcl | 67 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 67 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 13 |
| Sucralfate | Sucralfate | 65 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 12 |
| Fluconazole | Fluconazole | 64 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 45 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 63 | 16 |
| Methylprednisolone | Methylprednisolone | 62 | 57 |
| Azithromycin | Azithromycin | 60 | 45 |
| Metformin Hcl Er | Metformin Hcl | 60 | 13 |
| Metolazone | Metolazone | 60 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 60 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | suppressed |
| Novolog Flexpen | Insulin Aspart | 57 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 12 |
| Nifedipine Er | Nifedipine | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 52 | suppressed |
| Levemir | Insulin Detemir | 52 | 13 |
| Linzess | Linaclotide | 51 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 50 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 49 | suppressed |
| Chlorthalidone | Chlorthalidone | 48 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 16 |
| Ibuprofen | Ibuprofen | 48 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | suppressed |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 13 |
| Paliperidone Er | Paliperidone | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 14 |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Humalog | Insulin Lispro | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 31 |
| Insulin Aspart Flexpen | Insulin Aspart | 41 | 13 |
| Estradiol | Estradiol | 40 | suppressed |
| Movantik | Naloxegol Oxalate | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 39 | suppressed |
| Budesonide | Budesonide | 39 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 13 |
| Cephalexin | Cephalexin | 33 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Haloperidol | Haloperidol | 29 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Rytary | Carbidopa/Levodopa | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Entacapone | Entacapone | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Dulera | Mometasone/Formoterol | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Loxapine | Loxapine Succinate | 23 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 11 |
| Nystop | Nystatin | 22 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | 12 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 16 |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 13 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tacrolimus | Tacrolimus | 17 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Caplyta | Lumateperone Tosylate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluorometholone | Fluorometholone | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Pindolol | Pindolol | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Trinatal Rx 1 | Prenatal Vit27,calcium/Iron/Fa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.98 · 35 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INVEGA SUSTENNA, JARDIANCE, JOURNAVX, KISUNLA, LEQVIO, M-M-R II, OFEV, OTEZLA, PROQUAD, REPATHA, REXULTI, TZIELD, VAXELIS, VAXNEUVANCE, VRAYLAR, VYNDAQEL, Veozah, YUPELRI, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error